Skip to main content
Erschienen in: Journal of General Internal Medicine 1/2020

28.08.2019 | Original Research

Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial

verfasst von: David D. Odineal, MD, Maria T. Marois, PhD, MPH, Deborah Ward, PhD, RN, Christopher H. Schmid, PhD, Rima Cabrera, MSW, Ida Sim, PhD, MD, Youdan Wang, MS, Barth Wilsey, MD, Naihua Duan, PhD, Stephen G. Henry, MD, Richard L. Kravitz, MD, MSPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for chronic musculoskeletal pain, despite limited evidence of effectiveness and well-documented adverse effects. We assessed the effects of participating in a structured, personalized self-experiment (“N-of-1 trial”) on analgesic prescribing in patients with chronic musculoskeletal pain.

Methods

We randomized 215 patients with chronic pain to participate in an N-of-1 trial facilitated by a mobile health app or to receive usual care. Medical records of participating patients were reviewed at enrollment and 6 months later to assess analgesic prescribing. We established thresholds of ≥ 50, ≥ 20, and > 0 morphine milligram equivalents (MMEs) per day to capture patients taking relatively high doses only, patients taking low-moderate as well as relatively high doses, and patients taking any dose of opioids, respectively.

Results

There was no significant difference between the N-of-1 and control groups in the percentage of patients prescribed any opioids (relative odds ratio (ROR) = 1.05; 95% confidence interval [CI] = 0.61 to 1.80, p = 0.87). There was a clinically substantial but statistically not significant reduction of the percentage of patients receiving ≥ 20 MME (ROR = 0.58; 95% CI = 0.33 to 1.04, p = 0.07) and also in the percentage receiving ≥ 50 MME (ROR = 0.50; 95% CI = 0.19 to 1.34, p = 0.17). There was a significant reduction in the proportion of patients in the N-of-1 group prescribed NSAIDs compared with control (relative odds ratio = 0.53; 95% CI = 0.29 to 0.96, p = 0.04), with no concomitant increase in average pain intensity. There was no significant change in use of adjunctive medications (acetaminophen, gabapentenoids, or topicals).

Discussion

These exploratory results suggest that participation in N-of-1 trials may reduce long-term use of NSAIDs; there is also a weak signal for an effect on use of opioids. Additional research is needed to confirm these results and elucidate possible mechanisms.

Trial Registration

ClinicalTrials.​gov Identifier: NCT02116621.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J. Effective treatment options for musculoskeletal pain in primary care: a systematic overview of current evidence. PLoS One. 2017;12(6):e0178621.PubMedPubMedCentral Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J. Effective treatment options for musculoskeletal pain in primary care: a systematic overview of current evidence. PLoS One. 2017;12(6):e0178621.PubMedPubMedCentral
2.
Zurück zum Zitat Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872–82.PubMedPubMedCentral Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872–82.PubMedPubMedCentral
3.
Zurück zum Zitat Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.PubMed Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.PubMed
4.
Zurück zum Zitat Wiese A, Griffin M, Schaffner W, Stein M, Greevy R, Mitchel E, et al. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case–control study. Ann Intern Med. 2018;168(6):396–404.PubMedPubMedCentral Wiese A, Griffin M, Schaffner W, Stein M, Greevy R, Mitchel E, et al. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case–control study. Ann Intern Med. 2018;168(6):396–404.PubMedPubMedCentral
5.
Zurück zum Zitat DiJulio B, Wu B, Brodie M. The Washington Post/Kaiser Family Foundation Survey of Long-Term Prescription Painkiller Users and Their Household Members. The Henry J. Kaiser Family Foundation, 2016 December. Report No.: Contract No.: 8942. DiJulio B, Wu B, Brodie M. The Washington Post/Kaiser Family Foundation Survey of Long-Term Prescription Painkiller Users and Their Household Members. The Henry J. Kaiser Family Foundation, 2016 December. Report No.: Contract No.: 8942.
6.
Zurück zum Zitat Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86.PubMed Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86.PubMed
7.
Zurück zum Zitat Welsch P, Sommer C, Schiltenwolf M, Hauser W. Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week’s duration. Schmerz (Berlin, Germany). 2015;29(1):85–95. Welsch P, Sommer C, Schiltenwolf M, Hauser W. Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week’s duration. Schmerz (Berlin, Germany). 2015;29(1):85–95.
8.
Zurück zum Zitat Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial. JAMA. 2017;318(17):1661–7.PubMedPubMedCentral Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial. JAMA. 2017;318(17):1661–7.PubMedPubMedCentral
9.
Zurück zum Zitat Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. Bmj. 2017;357:j1909.PubMedPubMedCentral Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. Bmj. 2017;357:j1909.PubMedPubMedCentral
10.
Zurück zum Zitat Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.PubMed Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.PubMed
11.
Zurück zum Zitat Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. Bmj. 2016;354:i4857.PubMed Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. Bmj. 2016;354:i4857.PubMed
12.
Zurück zum Zitat Sondergaard KB, Weeke P, Wissenberg M, Schjerning Olsen AM, Fosbol EL, Lippert FK, et al. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacotherapy. 2017;3(2):100–7. Sondergaard KB, Weeke P, Wissenberg M, Schjerning Olsen AM, Fosbol EL, Lippert FK, et al. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacotherapy. 2017;3(2):100–7.
13.
Zurück zum Zitat Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Bmj. 2011;342:c7086.PubMedPubMedCentral Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Bmj. 2011;342:c7086.PubMedPubMedCentral
14.
Zurück zum Zitat Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Netw Open. 2019;2(2):e187896.PubMedPubMedCentral Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Netw Open. 2019;2(2):e187896.PubMedPubMedCentral
15.
Zurück zum Zitat Rios R, Zautra AJ. Socioeconomic disparities in pain: the role of economic hardship and daily financial worry. Health Psychol. 2011;30(1):58–66.PubMedPubMedCentral Rios R, Zautra AJ. Socioeconomic disparities in pain: the role of economic hardship and daily financial worry. Health Psychol. 2011;30(1):58–66.PubMedPubMedCentral
16.
Zurück zum Zitat Timmermans EJ, Schaap LA, Herbolsheimer F, Dennison EM, Maggi S, Pedersen NL, et al. The influence of weather conditions on joint pain in older people with osteoarthritis: results from the European Project on OSteoArthritis. J Rheumatol. 2015;42(10):1885–92.PubMed Timmermans EJ, Schaap LA, Herbolsheimer F, Dennison EM, Maggi S, Pedersen NL, et al. The influence of weather conditions on joint pain in older people with osteoarthritis: results from the European Project on OSteoArthritis. J Rheumatol. 2015;42(10):1885–92.PubMed
17.
Zurück zum Zitat Timmermans EJ, van der Pas S, Schaap LA, Sanchez-Martinez M, Zambon S, Peter R, et al. Self-perceived weather sensitivity and joint pain in older people with osteoarthritis in six European countries: results from the European Project on OSteoArthritis (EPOSA). BMC Musculoskelet Disord. 2014;15:66.PubMedPubMedCentral Timmermans EJ, van der Pas S, Schaap LA, Sanchez-Martinez M, Zambon S, Peter R, et al. Self-perceived weather sensitivity and joint pain in older people with osteoarthritis in six European countries: results from the European Project on OSteoArthritis (EPOSA). BMC Musculoskelet Disord. 2014;15:66.PubMedPubMedCentral
18.
Zurück zum Zitat Lee M, Ohde S, Urayama K, Takahashi O, Fukui T. Weather and health symptoms. Int J Environ Res Public Health. 2018;15(8):1670. Lee M, Ohde S, Urayama K, Takahashi O, Fukui T. Weather and health symptoms. Int J Environ Res Public Health. 2018;15(8):1670.
19.
Zurück zum Zitat Smith DM, Brown SL, Ubel PA. Mispredictions and misrecollections: challenges for subjective outcome measurement. Disabil Rehabil. 2008;30(6):418–24.PubMed Smith DM, Brown SL, Ubel PA. Mispredictions and misrecollections: challenges for subjective outcome measurement. Disabil Rehabil. 2008;30(6):418–24.PubMed
20.
Zurück zum Zitat Zucker DR, Ruthazer R, Schmid CH, Feuer JM, Fischer PA, Kieval RI, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006;33(10):2069–77.PubMed Zucker DR, Ruthazer R, Schmid CH, Feuer JM, Fischer PA, Kieval RI, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006;33(10):2069–77.PubMed
22.
Zurück zum Zitat Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig. 2012;32 Suppl 1:53–63.PubMed Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig. 2012;32 Suppl 1:53–63.PubMed
23.
Zurück zum Zitat Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med. 1985;102(4):520–8.PubMed Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med. 1985;102(4):520–8.PubMed
24.
Zurück zum Zitat Greene J, Hibbard JH, Sacks R, Overton V, Parrotta CD. When patient activation levels change, health outcomes and costs change, too. Health Aff. 2015;34(3):431–7. Greene J, Hibbard JH, Sacks R, Overton V, Parrotta CD. When patient activation levels change, health outcomes and costs change, too. Health Aff. 2015;34(3):431–7.
25.
Zurück zum Zitat Barr C, Marois M, Sim I, Schmid CH, Wilsey B, Ward D, et al. The PREEMPT Study—evaluating smartphone-assisted N-of-1 trials in patients with chronic pain: study protocol for a randomized controlled trial. Trials. 2015;16:67.PubMedPubMedCentral Barr C, Marois M, Sim I, Schmid CH, Wilsey B, Ward D, et al. The PREEMPT Study—evaluating smartphone-assisted N-of-1 trials in patients with chronic pain: study protocol for a randomized controlled trial. Trials. 2015;16:67.PubMedPubMedCentral
26.
Zurück zum Zitat Kravitz RL, Schmid CH, Marois M, Wilsey B, Ward D, Hays RD, Duan N, Wang Y, MacDonald S, Jerant A, Servadio JL. Effect of mobile device-supported single-patient multi-crossover trials on treatment of chronic musculoskeletal pain: a randomized clinical trial. JAMA Intern Med. 2018;178(10):1368–77. Kravitz RL, Schmid CH, Marois M, Wilsey B, Ward D, Hays RD, Duan N, Wang Y, MacDonald S, Jerant A, Servadio JL. Effect of mobile device-supported single-patient multi-crossover trials on treatment of chronic musculoskeletal pain: a randomized clinical trial. JAMA Intern Med. 2018;178(10):1368–77.
27.
Zurück zum Zitat Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):480–92.PubMed Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):480–92.PubMed
28.
Zurück zum Zitat Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ. Overview review: comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain. 2015;19(9):1213–23.PubMed Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ. Overview review: comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain. 2015;19(9):1213–23.PubMed
29.
Zurück zum Zitat Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, et al. Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2017;14(8):e1002369.PubMedPubMedCentral Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, et al. Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2017;14(8):e1002369.PubMedPubMedCentral
30.
Zurück zum Zitat Derry S, Wiffen PJ, Kalso EA, Bell RF, Aldington D, Phillips T, et al. Topical analgesics for acute and chronic pain in adults—an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;5:CD008609.PubMed Derry S, Wiffen PJ, Kalso EA, Bell RF, Aldington D, Phillips T, et al. Topical analgesics for acute and chronic pain in adults—an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;5:CD008609.PubMed
31.
Zurück zum Zitat Gudin JA, Brennan MJ, Harris ED, Hurwitz PL, Dietze DT, Strader JD. Reduction of opioid use and improvement in chronic pain in opioid-experienced patients after topical analgesic treatment: an exploratory analysis. Postgrad Med. 2018;130(1):42–51.PubMed Gudin JA, Brennan MJ, Harris ED, Hurwitz PL, Dietze DT, Strader JD. Reduction of opioid use and improvement in chronic pain in opioid-experienced patients after topical analgesic treatment: an exploratory analysis. Postgrad Med. 2018;130(1):42–51.PubMed
32.
Zurück zum Zitat Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016;4:CD007400.PubMed Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016;4:CD007400.PubMed
33.
Zurück zum Zitat Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733–8.PubMedPubMedCentral Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733–8.PubMedPubMedCentral
35.
Zurück zum Zitat Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data. PLoS One. 2017;12(4):e0174426.PubMedPubMedCentral Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data. PLoS One. 2017;12(4):e0174426.PubMedPubMedCentral
36.
Zurück zum Zitat Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–7.PubMed Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–7.PubMed
37.
Zurück zum Zitat Reuben DB, Alvanzo AA, Ashikaga T, Bogat GA, Callahan CM, Ruffing V, et al. National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med. 2015;162(4):295–300.PubMed Reuben DB, Alvanzo AA, Ashikaga T, Bogat GA, Callahan CM, Ruffing V, et al. National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med. 2015;162(4):295–300.PubMed
38.
Zurück zum Zitat Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT, Sullivan MD, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75.PubMedPubMedCentral Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT, Sullivan MD, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75.PubMedPubMedCentral
39.
Zurück zum Zitat Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440–9.PubMedPubMedCentral Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440–9.PubMedPubMedCentral
40.
Zurück zum Zitat Guy GP Jr., Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697–704.PubMedPubMedCentral Guy GP Jr., Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697–704.PubMedPubMedCentral
41.
Zurück zum Zitat Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Banfield E, et al. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart. 2017;4(1):e000550.PubMedPubMedCentral Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Banfield E, et al. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart. 2017;4(1):e000550.PubMedPubMedCentral
42.
Zurück zum Zitat Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–9.PubMed Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–9.PubMed
43.
Zurück zum Zitat Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70(10):1159–72.PubMed Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70(10):1159–72.PubMed
44.
Zurück zum Zitat Kaufman DW, Kelly JP, Battista DR, Malone MK, Weinstein RB, Shiffman S. Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiol Drug Saf. 2018;27(3):322–31.PubMed Kaufman DW, Kelly JP, Battista DR, Malone MK, Weinstein RB, Shiffman S. Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiol Drug Saf. 2018;27(3):322–31.PubMed
45.
Zurück zum Zitat Rasmussen-Barr E, Held U, Grooten WJ, Roelofs PD, Koes BW, van Tulder MW, et al. Non-steroidal anti-inflammatory drugs for sciatica. Cochrane Database Syst Rev.. 2016;10:Cd012382.PubMed Rasmussen-Barr E, Held U, Grooten WJ, Roelofs PD, Koes BW, van Tulder MW, et al. Non-steroidal anti-inflammatory drugs for sciatica. Cochrane Database Syst Rev.. 2016;10:Cd012382.PubMed
46.
Zurück zum Zitat Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531–9.PubMed Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531–9.PubMed
47.
Zurück zum Zitat Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med.. 2007;120(3):280.e1–7. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med.. 2007;120(3):280.e1–7.
48.
Zurück zum Zitat Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. JAMA. 2016;315(15):1624–45.PubMedPubMedCentral Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. JAMA. 2016;315(15):1624–45.PubMedPubMedCentral
50.
Zurück zum Zitat Davis MS. Variations in patients’ compliance with doctors’ advice: an empirical analysis of patterns of communication. Am J Public Health Nations Health. 1968;58(2):274–88.PubMedPubMedCentral Davis MS. Variations in patients’ compliance with doctors’ advice: an empirical analysis of patterns of communication. Am J Public Health Nations Health. 1968;58(2):274–88.PubMedPubMedCentral
51.
Zurück zum Zitat Whitney RL, Ward DH, Marois MT, Schmid CH, Sim I, Kravitz RL. Patient perceptions of their own data in mhealth technology-enabled N-of-1 trials for chronic pain: qualitative study. JMIR Mhealth Uhealth. 2018;6(10):e10291.PubMedPubMedCentral Whitney RL, Ward DH, Marois MT, Schmid CH, Sim I, Kravitz RL. Patient perceptions of their own data in mhealth technology-enabled N-of-1 trials for chronic pain: qualitative study. JMIR Mhealth Uhealth. 2018;6(10):e10291.PubMedPubMedCentral
Metadaten
Titel
Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial
verfasst von
David D. Odineal, MD
Maria T. Marois, PhD, MPH
Deborah Ward, PhD, RN
Christopher H. Schmid, PhD
Rima Cabrera, MSW
Ida Sim, PhD, MD
Youdan Wang, MS
Barth Wilsey, MD
Naihua Duan, PhD
Stephen G. Henry, MD
Richard L. Kravitz, MD, MSPH
Publikationsdatum
28.08.2019
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 1/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05303-0

Weitere Artikel der Ausgabe 1/2020

Journal of General Internal Medicine 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.